Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach

Allergan ($AGN) is adding to its dry-eye lineup with a new purchase agreement. The company has bet $125 million on a new approach to the disease, picking up Oculeve and lead candidate OD-01--a nerve-stimulating implant placed in the nose. More from FierceBiotech

Suggested Articles

Novartis is joining a group of drugmakers already advertising cancer treatments on TV with the launch of its Piqray campaign. 

With Johnson & Johnson battling talc and opioid lawsuits and now a Risperdal verdict, is the brand facing a decline?

Transparency in drug pricing sounds like a great idea, but a new study finds that almost none of the state laws provide real price insights.